Abstract
Seventy-seven patients with small cell lung cancer were entered on a protocol comprising induction chemotherapy with cyclophosphamide 1 g m−2, adriamycin 40 mg mt-2 and vincristine 1.4 mg mt-2 (CAV) every 21 days for four to six cycles. The overall response rate was 72.8%. Twenty-six patients achieving complete remission received intensification with two further cycles of ifosfamide 5 g mt-2, mesna 8 g mt-2, methotrexate 30 mg mt-2 and etoposide 100 mg mt-2 per day for 3 days (IME). Six of the 15 patients in partial remission following CAV achieved a further remission on IME (response rate 40%). Median survival in the limited disease group was 11 months compared with 7 months in the extensive disease patients and four patients are alive at more than 2 yr follow up. There was no significant prolongation of the median survival (11 months) seen in those patients in complete remission who had negative second bronchoscopy examination. This sequential six drug regime produces high response rates in small cell lung cancer, and there is evidence of lack of cross-resistance between CAV and IME.
Similar content being viewed by others
References
Mersey Regional Cancer Registry.Interim Report 1974–1982.
Mostyn G, Ihde D C, Lichter A S, Bunn P A,et al: Small cell lung cancer 1973–1983: early progress and recent results.Int J radiat Oncol biol Phys 10, 515 (1984).
Vogelsgang G B, Abeloff M D, Ettinger D S, Booker S V: Long-term survivors of small cell carcinoma of the lung.Am J Med 79, 49 (1985).
Greco F A, Richardson R L: Treatment of oat-cell carcinoma of lung: complete remissions, acceptable complications and improved survival.Br Med J 2, 10 (1978).
Cantwell B, Harris A, Bozzino J M, Corris P, Nariman S, Pearce S, Gibson J, Hendrick D: High dose Ifosfamide and Mesna as crossover therapy after Adriamycin, VP16-213 and Vincristine (VP-AV) for small cell lung cancer.Proc Am Assoc clin Oncol 216 (1984).
Arnold, A M: General review: podophyllotoxin derivative VP-16-213.Cancer Chemother Pharmac 3, 71 (1979).
Cavalli F, Sonntag R W, Jungi F, Senn H J, Brunner K W: VP-16-213 chemotherapy for remission induction of small cell lung cancer. A randomised trial using three dosage schedules.Cancer Treat Rep 62, 473 (1978).
Maurer L H, Tulloh M, Weiss R B, Blom J, Leone L, Glidwell O, Pajak T F: A randomised combined trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus maintenance chemotherapy and prophylactic whole brain irradiation.Cancer 45, 30 (1980).
Cabanillas F, Burgess M A, Bodey G P, Freireich E J: Sequential chemotherapy and later intensification for malignant lymphomas of aggressive histologic type.Am J Med 74, 382 (1983).
Hansen H, Rorth M: Lung cancer. In Pinedo H M, Chabner B Aet al (eds): Cancer Chemotherapy, Vol. 17, p. 302. Amsterdam, Elsevier (1985).
Jackson D V, Zekan P J, Caldwell R D, Slatkoff M C,et al: VP16-213 in combination chemotherapy with chest irradiation for small cell lung cancer: a randomised trial of the Piedmont Oncology Association.J clin Oncol 2, 1343 (1984).
Evans W K, Shepherd F A, Feld R, Osoba D, DeBoer G: First line therapy with VP-16 and cisplatin for small cell lung cancer.Sem Oncol 13 (suppl 3), 17 (1986).
Cantwell B M J, Bozzino J M, Corris P, Harris A C: The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after IV16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.Eur J Cancer clin Oncol 24, 123 (1988).
Fox R N, Woods R L, Brodie G W, Tattersall M H: A randomised study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy.Int J radial Oncol biol Phys 6 1083 (1980).
Souhami R L, Geddes D M, Spiro S G,et al: Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial.Br Med J 288, 1643 (1984).
Bunn P A, Lichter A S, Makuch R W, Martin H,et al: Chemotherapy alone or Chemotherapy with chest radiation therapy in limited stage small cell lung cancer.Ann intern Med 106, 655 (1987).
Perez C A, Emism L, Oldham R K: Randomised trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report.J clin Oncol 2, 1200 (1986).
Perry M C, Eaton W L, Propert K J, Ware J H,et al: Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung.New Engl J Med 316, 912 (1987).
Valdivieso M, Cabanillas F, Keating M, Barkley H T.et al: Intensive chemotherapy of extensive small cell bronchogenic carcinoma in protected environment units.Am J Med 76, 405 (1984).
Klastersky J, Nicaise C, Longeral E, Stryckmans P: Cisplatin, adriamycin and etoposide for remission of small cell bronchogenic carcinoma.Cancer 50, 652 (1982).
Sculier J P, Klastersky J, Stryckmans P: Late intensification in small cell lung cancer: a phase I study of high dose of cyclophosphamide and etoposide with autologous bone marrow transplantation.J clin Oncol 3, 184 (1985).
Spitzer G, Dicke K A, Litam J, Verma D S,et al. High dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumours.Cancer 45, 3075 (1988).
Ihde D C, Deisseroth A B, Lichter A S, Bunn P A,et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive stage small cell lung cancer.J clin Oncol 4, 1443 (1986).
Smith I E, Evans B D, Harland S J: High dose cyclophosphamide with autologous bone marrow in patients with small cell lung cancer.Cancer Chemother Pharmac 14, 120 (1985).
Einhorn L H: Initial therapy with cisplatin plus VP-16 in small cell lung cancer.Sem Oncol 13 (suppl 3), 5 (1986).
Humblet Y, Symann M, Bosly A, Delaunois L,et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomised study.J clin Oncol 5, 1864 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hardman, P.D.J., Green, J.A., Errington, R.D. et al. Treatment of small cell lung cancer with induction chemotherapy followed by late intensification. Med. Oncol. & Tumor Pharmacother. 6, 227–232 (1989). https://doi.org/10.1007/BF02985195
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02985195